-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $15

Benzinga·06/30/2026 17:29:19
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $15.